{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:42:12Z","timestamp":1788576132408,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["2022HXFH001"],"award-info":[{"award-number":["2022HXFH001"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>For patients with low- and intermediate-risk stage II\/III rectal cancer, current studies have reached a consensus that preoperative radiotherapy may be dispensed with, and neoadjuvant chemotherapy (NCT) alone might achieve an accepted local control. Our previous phase II study has evidenced that the morphological response of NCT could be better judged at a relatively early stage. Low- and intermediate-risk stage II\/III rectal cancer patients could achieve a high rate of tumor shrinkage and downgrade after only 4 cycles of NCT and obvious tumor morphological changes could be observed after 2 cycles of NCT. However, there is still a lack of more detailed stratification and evidence for pathological criteria. The aim of the present study (comparison of the pathological response to 2 or 4 cycles of neoadjuvant CAPOX in II\/III rectal cancer patients with low\/intermediate risks, COPEC trial) is to determine the pathological tumor regression grade (pTRG) rate of 2 or 4 cycles of NCT in low- and intermediate-risk stage II\/III rectal cancer and verify the feasibility of early identification of chemotherapy-insensitive population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>This is a multicenter, prospective, non-inferior, randomized controlled trial (RCT) initiated by West China Hospital of Sichuan University and designed to be conducted in fourteen hospitals around China. Eligible patients will be centrally randomized into 2 or 4 cycles of CAPOX in a 1:1 ratio using the central automated randomization system offered by the O-trial online system (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/plus.o-trial.com\/\">https:\/\/plus.o-trial.com\/<\/jats:ext-link>) and accept total mesorectal excision after 2 or 4 cycles of CAPOX (oxaliplatin 130\u00a0mg\/m<jats:sup>2<\/jats:sup>, once daily on day 1, every 21\u00a0days and capecitabine 1000\u00a0mg\/m<jats:sup>2<\/jats:sup>, twice daily on days 1 to 14, every 21\u00a0days). The primary endpoint is the proportion of patients with pathological no-tumor regression (pTRG 3), which is determined postoperatively by each sub-center and verified by the primary center.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>COPEC trial is designed to verify that the preoperative CAPOX chemotherapy for low- and intermediate-risk stage II\/III rectal cancer could achieve a good response judgment after 2 cycles and obtain the tumor pathological response rate after 2 cycles of CAPOX. We hope the COPEC trial could help in establishing a consensus standard of low- and intermediate-risk rectal cancer and the early identification of stage II\/III rectal patients with low- and intermediate-risk who are poorly responding to NCT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinicaltrial.gov NCT04922853. Registered on June 4, 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07405-x","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T07:01:54Z","timestamp":1686639714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of the pathological response to 2 or 4 cycles of neoadjuvant CAPOX in II\/III rectal cancer patients with low\/intermediate risks: study protocol for a prospective, non-inferior, randomized control trial (COPEC trial)"],"prefix":"10.1186","volume":"24","author":[{"given":"Yu","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingtian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"COPEC groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"7405_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638\u201346.","journal-title":"N Engl J Med"},{"key":"7405_CR2","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731\u201340.","journal-title":"N Engl J Med"},{"key":"7405_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0140-6736(09)60484-0","volume":"373","author":"D Sebag-Montefiore","year":"2009","unstructured":"Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811\u201320.","journal-title":"Lancet"},{"key":"7405_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","volume":"12","author":"W Van Gijn","year":"2011","unstructured":"Van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575\u201382.","journal-title":"Lancet Oncol"},{"key":"7405_CR5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.6004\/jnccn.2018.0061","volume":"16","author":"AB Benson","year":"2018","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:874\u2013901.","journal-title":"J Natl Compr Canc Netw."},{"key":"7405_CR6","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/DCR.0b013e31820eeb37","volume":"54","author":"FJ Fleming","year":"2011","unstructured":"Fleming FJ, P\u00e5hlman L, Monson JR. Neoadjuvant therapy in rectal cancer. Dis Colon Rectum. 2011;54:901\u201312.","journal-title":"Dis Colon Rectum"},{"key":"7405_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1200\/JCO.2014.60.1054","volume":"33","author":"JJ Smith","year":"2015","unstructured":"Smith JJ, Garcia-Aguilar J. Advances and challenges in treatment of locally advanced rectal cancer. J Clin Oncol. 2015;33:1797\u2013808.","journal-title":"J Clin Oncol"},{"key":"7405_CR8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/SLA.0000000000003649","volume":"272","author":"X Deng","year":"2020","unstructured":"Deng X, Liu P, Jiang D, Wei M, Wang X, Yang X, et al. Neoadjuvant radiotherapy versus surgery alone for stage II\/III mid-low rectal cancer with or without high-risk factors: a prospective multicenter stratified randomized trial. Ann Surg. 2020;272:1060\u20139.","journal-title":"Ann Surg"},{"key":"7405_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/SLA.0b013e31820b8d52","volume":"253","author":"FG Taylor","year":"2011","unstructured":"Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter. Eur Stud Ann Surg. 2011;253:711\u20139.","journal-title":"Eur Stud Ann Surg"},{"key":"7405_CR10","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1002\/cncr.25866","volume":"117","author":"M Frasson","year":"2011","unstructured":"Frasson M, Garcia-Granero E, Roda D, Flor-Lorente B, Rosello S, Esclapez P, et al. Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. Cancer. 2011;117:3118\u201325.","journal-title":"Cancer"},{"key":"7405_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.clcc.2016.02.003","volume":"15","author":"D Bosse","year":"2016","unstructured":"Bosse D, Mercer J, Raissouni S, Dennis K, Goodwin R, Jiang D, et al. PROSPECT eligibility and clinical outcomes: results from the Pan-Canadian Rectal Cancer Consortium. Clin Colorectal Canc. 2016;15:243\u20139.","journal-title":"Clin Colorectal Canc"},{"key":"7405_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s10350-004-0086-6","volume":"47","author":"TD Cecil","year":"2004","unstructured":"Cecil TD, Sexton R, Moran BJ, Heald RJ. Total mesorectal excision results in low local recurrence rates in lymph node-positive rectal cancer. Dis Colon Rectum. 2004;47:1145\u20139 (discussion 9-50).","journal-title":"Dis Colon Rectum."},{"key":"7405_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2019.08.020","volume":"122","author":"AC Lord","year":"2019","unstructured":"Lord AC, Graham Mart\u00ednez C, D\u2019Souza N, Pucher PH, Brown G, Nagtegaal ID. The significance of tumour deposits in rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis. Eur J Cancer (Oxford, England: 1990). 2019;122:1\u20138.","journal-title":"Eur J Cancer (Oxford, England: 1990)."},{"key":"7405_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2018.07.131","volume":"104","author":"MRS Siddiqui","year":"2018","unstructured":"Siddiqui MRS, Simillis C, Bhoday J, Battersby NJ, Mok J, Rasheed S, et al. A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours. Eur J Cancer. 2018;104:47\u201361.","journal-title":"Eur J Cancer"},{"key":"7405_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1200\/JCO.2007.13.5434","volume":"26","author":"JG Guillem","year":"2008","unstructured":"Guillem JG, Diaz-Gonzalez JA, Minsky BD, Valentini V, Jeong SY, Rodriguez-Bigas MA, et al. cT3N0 rectal cancer: potential overtreatment with Preoperative chemoradiotherapy is warranted. J Clin Oncol. 2008;26:368\u201373.","journal-title":"J Clin Oncol"},{"key":"7405_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/bjs\/znab388","volume":"109","author":"X Deng","year":"2021","unstructured":"Deng X, Wu Q, Bi L, Yu Y, Huang S, He D, et al. Early response to upfront neoadjuvant chemotherapy (CAPOX) alone in low- and intermediate-risk rectal cancer: a single-arm phase II trial. Br J Surg. 2021;109:121\u20138.","journal-title":"Br J Surg"},{"key":"7405_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s13063-017-2085-2","volume":"18","author":"NJ Battersby","year":"2017","unstructured":"Battersby NJ, Dattani M, Rao S, Cunningham D, Tait D, Adams R, et al. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials. 2017;18:394.","journal-title":"Trials"},{"key":"7405_CR18","doi-asserted-by":"publisher","unstructured":"Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 2013;100:1009\u201314. https:\/\/doi.org\/10.1002\/bjs.9192.","DOI":"10.1002\/bjs.9192"},{"key":"7405_CR19","doi-asserted-by":"publisher","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","volume":"28","author":"R Glynne-Jones","year":"2017","unstructured":"Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22\u201340.","journal-title":"Ann Oncol."},{"key":"7405_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.21147\/j.issn.1000-9604.2019.01.07","volume":"31","author":"Diagnosis, Treatment Guidelines For Colorectal Cancer Working Group C","year":"2019","unstructured":"Diagnosis, Treatment Guidelines For Colorectal Cancer Working Group C. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version). Chin J Cancer Res. 2019;31:117\u201334.","journal-title":"Chin J Cancer Res"},{"key":"7405_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"7405_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1023\/A:1008890401133","volume":"7","author":"MA Sprangers","year":"1998","unstructured":"Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, Aaronson NK. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. Qual Life Res. 1998;7:291\u2013300.","journal-title":"Qual Life Res."},{"key":"7405_CR23","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1007\/s00520-016-3270-7","volume":"24","author":"V Ganesh","year":"2016","unstructured":"Ganesh V, Agarwal A, Popovic M, Cella D, McDonald R, Vuong S, et al. Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review. Support Care Cancer. 2016;24:3661\u20138.","journal-title":"Support Care Cancer"},{"key":"7405_CR24","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ Jr, O\u2019Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549\u201357 (discussion 64).","journal-title":"J Urol."},{"key":"7405_CR25","volume-title":"Sample size calculations in clinical research. 2nd ed: chapman and hall\/CRC","author":"S-C Chow","year":"2008","unstructured":"Chow S-C, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research. 2nd ed: chapman and hall\/CRC. 2008."},{"key":"7405_CR26","doi-asserted-by":"publisher","first-page":"3223-+","DOI":"10.1200\/JCO.18.02309","volume":"37","author":"YH Deng","year":"2019","unstructured":"Deng YH, Chi P, Lan P, Wang L, Chen WQ, Cui L, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019;37:3223-+.","journal-title":"J Clin Oncol."},{"key":"7405_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00280-017-3243-7","volume":"79","author":"J Koike","year":"2017","unstructured":"Koike J, Funahashi K, Yoshimatsu K, Yokomizo H, Kan H, Yamada T, et al. Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II\/III rectal cancer: the FACT trial. Cancer Chemother Pharmacol. 2017;79:519\u201325.","journal-title":"Cancer Chemother Pharmacol"},{"key":"7405_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/DCR.0000000000000849","volume":"60","author":"P Rouanet","year":"2017","unstructured":"Rouanet P, Rullier E, Lelong B, Maingon P, Tuech JJ, Pezet D, et al. Tailored treatment strategy for locally advanced rectal carcinoma based on the tumor response to induction chemotherapy: preliminary results of the French phase II multicenter GRECCAR4 trial. Dis Colon Rectum. 2017;60:653\u201363.","journal-title":"Dis Colon Rectum"},{"key":"7405_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ejso.2016.02.014","volume":"42","author":"T Kamiya","year":"2016","unstructured":"Kamiya T, Uehara K, Nakayama G, Ishigure K, Kobayashi S, Hiramatsu K, et al. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study. Ejso-Eur J Surg Onc. 2016;42:829\u201335.","journal-title":"Ejso-Eur J Surg Onc"},{"key":"7405_CR30","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/jjco\/hyt115","volume":"43","author":"K Uehara","year":"2013","unstructured":"Uehara K, Hiramatsu K, Maeda A, Sakamoto E, Inoue M, Kobayashi S, et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol. 2013;43:964\u201371.","journal-title":"Jpn J Clin Oncol"},{"key":"7405_CR31","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00280-014-2417-9","volume":"73","author":"J Hasegawa","year":"2014","unstructured":"Hasegawa J, Nishimura J, Mizushima T, Miyake Y, Kim HM, Takemoto H, et al. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol. 2014;73:1079\u201387.","journal-title":"Cancer Chemother Pharmacol"},{"key":"7405_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.2013.51.7904","volume":"32","author":"D Schrag","year":"2014","unstructured":"Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513\u20138.","journal-title":"J Clin Oncol"},{"key":"7405_CR33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/annonc\/mdw616","volume":"28","author":"UB Patel","year":"2017","unstructured":"Patel UB, Brown G, Machado I, Santos-Cores J, Pericay C, Ballesteros E, et al. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. Ann Oncol. 2017;28:344\u201353.","journal-title":"Ann Oncol"},{"key":"7405_CR34","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1186\/s12885-019-6424-4","volume":"19","author":"T Shiraishi","year":"2019","unstructured":"Shiraishi T, Sasaki T, Ikeda K, Tsukada Y, Nishizawa Y, Ito M. Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer. BMC Cancer. 2019;19:1222.","journal-title":"BMC Cancer"},{"key":"7405_CR35","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1245\/s10434-017-5967-3","volume":"24","author":"S Hasegawa","year":"2017","unstructured":"Hasegawa S, Goto S, Matsumoto T, Hida K, Kawada K, Matsusue R, et al. A multicenter phase 2 study on the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Ann Surg Oncol. 2017;24:3587\u201395.","journal-title":"Ann Surg Oncol"},{"key":"7405_CR36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000430469","volume":"32","author":"T Matsumoto","year":"2015","unstructured":"Matsumoto T, Hasegawa S, Zaima M, Inoue N, Sakai Y. Outcomes of neoadjuvant chemotherapy without radiation for rectal cancer. Digest Surg. 2015;32:275\u201383.","journal-title":"Digest Surg"},{"key":"7405_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1740774518824539","volume":"16","author":"D Schrag","year":"2019","unstructured":"Schrag D, Weiser M, Saltz L, Mamon H, Gollub M, Basch E, et al. Challenges and solutions in the design and execution of the PROSPECT phase II\/III neoadjuvant rectal cancer trial (NCCTG N1048\/Alliance). Clin Trials. 2019;16:165\u201375.","journal-title":"Clin Trials"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07405-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07405-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07405-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T07:03:06Z","timestamp":1686639786000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07405-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7405"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07405-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"12 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial has been approved by the Ethics Committee of the West China Hospital, Sichuan University (2021 No. 376). Each participant has signed an ICF before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"397"}}